CGEM
Cullinan Therapeutics, Inc.
NASDAQ · USHealthcareMedical - Pharmaceuticals
$17.50-1.07%
Price as of Jul 20, 2026
CGEM growth
Cullinan Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -9.2%
- EBIT
- -15.0%
- EPS
- -21.4%
- Free cash flow
- -19.0%
- Operating cash flow
- -18.9%
Forward estimates
- Revenue
- —
- EBITDA
- +106.7%
- EPS
- +16.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -31.4%
- EBIT
- -22.7%
- Net income
- -31.4%
- EPS
- -19.6%
- Free cash flow
- -21.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.